| Role of interferon-alfa in NHL: still controversial? | |
| | |
MedLine Citation:
|
PMID: 10499247 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Recombinant interferon-alfa (Intron A, Roferon-A) has been under investigation as a therapeutic agent for non-Hodgkin's lymphoma (NHL) for 25 years. It has antitumor efficacy in a number of histologic subtypes but has not been accepted as a clinically useful agent by the majority of oncologists/hematologists. A total of 10 prospective, randomized trials of interferon-alfa have been conducted in patients with follicular lymphoma. A survival benefit associated with interferon-alfa has been demonstrated in three of these trials, which used an anthracycline-based combination chemotherapy induction regimen, primarily in patients with bulky symptomatic disease. In this article, we review these trials, as well as the use of interferon-alfa in other NHL subtypes. Based on these data, we support the recommendation that interferon-alfa be added to an anthracycline-based induction regimen in the treatment of patients with clinically or histologically aggressive follicular lymphoma. This agent also appears to be effective in patients with diffuse large B-cell lymphoma and in patients with cutaneous T-cell lymphoma. Preliminary clinical data support the need for prospective, randomized phase III trials evaluating the role of interferon-alfa in these disorders. |
| | |
Authors:
|
S Haase-Statz; R V Smalley |
Related Documents
:
|
19169287 - Autologous transplantation for relapsed non-hodgkin's lymphoma using intravenous busulf... 21857347 - Open versus laparoscopic pelvic lymph node dissection in early stage cervical cancer: n... 22095247 - Cervical stromal involvement can predict survival in advanced endometrial carcinoma: a ... 15154737 - Editorial perspective--advances in b-cell non-hodgkin's lymphoma. 16673237 - Low-grade gliomas -- current concepts. 8841507 - The value of prognostic factors in the management of stage i nonseminomatous germ cell ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Oncology (Williston Park, N.Y.) Volume: 13 ISSN: 0890-9091 ISO Abbreviation: Oncology (Williston Park, N.Y.) Publication Date: 1999 Aug |
Date Detail:
|
Created Date: 1999-10-21 Completed Date: 1999-10-21 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8712059 Medline TA: Oncology (Williston Park) Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1147-59; discussion 1159-60, 1163 Citation Subset: IM |
Affiliation:
|
Synertron, Inc., Madison, Wisconsin, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
administration & dosage,
therapeutic use* Antineoplastic Combined Chemotherapy Protocols / therapeutic use Humans Interferon-alpha / administration & dosage, therapeutic use* Lymphoma, B-Cell / drug therapy Lymphoma, Follicular / drug therapy Lymphoma, Non-Hodgkin / classification, drug therapy* Lymphoma, T-Cell / drug therapy Randomized Controlled Trials as Topic Survival Analysis |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Interferon-alpha |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mounting evidence for postmastectomy locoregional radiation therapy.
Next Document: Some elements of prognosis in terminal cancer.